CRX.L Regulatory News (CRX)

25 Feb 2008 07:00

Cyprotex PLC25 February 2008 CYPROTEX plc NEWS 25 February 2008 Cyprotex starts working with the NIH Chemical Genomics Centre Cyprotex is pleased to announce that it has been chosen to work with theNational Institutes of Health Chemical Genomics Centre (NCGC), based inRockville, Maryland USA. The NCGC has been established by the National Institute of Health, with a viewto creating a national resource in chemical probe development. The centre usesthe latest industrial-scale technologies in order to collect data for definingthe cross-section between chemical space and biological activity. Cyprotex's automated facilities satisfy the NCGC's requirements by providingexceptionally robust data and rapid turnaround while profiling the in vitroproperties of a wide range of compounds. The data generated by Cyprotex will then be published on the PubChem website(http://pubchem.ncbi.nlm.nih.gov/), a National Centre for BiotechnologyInformation (NCBI) program providing public information on the biologicalactivities of small molecules. Commenting on the agreement, Robert Morrison Atwater, CEO of Cyprotex plc said:"We are looking forward to initiating this new relationship with NIH and aredelighted that Cyprotex has been chosen as their partner for this valuable andexciting project." Cyprotex is a specialist provider of ADME (Absorption, Distribution, Metabolismand Excretion) screening and predictive services. Its unique Cloe(R) technology,based on a highly automated laboratory and IT software platform, ensures optimalperformance and quality of our services for our clients. This is now beingrecognised within the industry leading to a rapid expansion of our customerbase. For further information:Cyprotex PLCHelen Gill PhD, Product Development ManagerTel: +44 (0)1625 505 100h.gill@cyprotex.comwww.cyprotex.com Notes to editors: The NCGC: The NIH Chemical Genomics Centre (NCGC) is an ultrahigh-throughput screeningcentre that generates chemical probes of gene and cell functions in health anddisease, and catalyzes for drug development for neglected rare and orphandiseases. Collaborating with an enormous diversity of biomedical researchersworldwide, the NCGC brings a biopharmaceutical approach to academic chemicalbiology and drug discovery, utilizing state-of-the-art assay technologies, aunique and fully automated robotic screening paradigm and informatics platform,and parallel synthetic and analytical chemistry to discover and develop novelcompounds. In order to drive maximum innovation the NCGC makes both its data andits chemical probes publicly available without restriction. In addition, inorder to address the systematic inefficiencies in these early steps of the drugdevelopment process, the NCGC develops new paradigms for high-throughputscreening, informatics, and chemistry, such as the Centre's Quantitative HighThroughput Screening (qHTS) paradigm. Bringing together the best of academic andpharmaceutical research to bridge the translational divide, the NCGC is bringingthe potential of the Human Genome Project to reality for scientists, patients,and the public. This information is provided by RNS The company news service from the London Stock Exchange